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1. Introduction
Prokineticin 2 (PROK2) is a peptide that is widely distributed in the
nervous system and influences a variety of brain functions, such as pain,
food intake and circadian rhythms (Negri and Lattanzi, 2012; Negri and
Ferrara, 2018). PROK2 is able to mediate its signaling through two
different G-protein coupled receptors (GPCR), designated prokineticin
receptor 1 (PKR1) and prokineticin receptor 2 (PKR2) (Masuda et al.,
2002; Soga et al., 2002). They activate multiple intracellular signal-
transduction pathways promoting intracellular calcium mobilization
(Masuda et al., 2002; Negri and Lattanzi, 2012) by Gαq coupling; they
also induce STAT3 activation coupling to Gαi (especially PKR2) and
AMPc production by Gαs proteins (Lin et al., 2002; Negri and Ferrara,
2018; Lattanzi et al., 2018). These two receptors have different tissue
distributions: PKR1 is expressed in diverse peripheral organs with re-
latively high levels in the small intestine and lung, whereas PKR2 is
predominantly expressed in the central nervous system (Masuda et al.,
2002; Soga et al., 2002; Negri and Lattanzi, 2012). In-
tracerebroventricular (i.c.v.) injection of Amyloid β1–42 (Aβ1–42) in rat
is a well-established animal model of Alzheimer's disease (AD). Pre-
vious our studies have reported that following Aβ1–42 i.c.v. injection,
the levels of PROK2 and its receptors were significantly increased in rat
brain hippocampus, suggesting that modulation of the prokineticin
system could be a general response to Aβ injury (Severini et al., 2015).
In this work, by PCR amplification from rat hippocampus cDNA, we
identified a PKR2 splice variant, which lacking the second exon gives
rise to a protein comprising only four transmembrane elements, de-
nominated TM 4–7. So, we have expressed TM 4–7 protein in yeast,
explored its dimerization relationship with PKR2 and evaluated its role
on PK signaling. We finally evaluated the expression of TM 4–7 in
hippocampus of rats Aβ1–42 i.c.v. injected and its influence on proki-
neticin signal transduction.
2. Materials and methods
2.1. Chemical reagents and media
Aβ1–42 peptide was purchased from Abcam (Abcam, Cambridge,
UK). 1 mg/ml Aβ1–42 peptide stock solutions were prepared in
Phosphate-Buffered Saline, PBS (0.01M NaH2PO4, 0.15M NaCl,
pH 7.4) and incubated at 37 °C for 72 h before use. This procedure is
known to produce insoluble precipitates and to facilitate markedly the
appearance of learning deficits in several tasks (Severini et al., 2015).
Glass beads (425–600 μm, acid-washed), yeast nitrogen base, Ripa
buffer, protease inhibitors, fluorescein di-β-D-galactopyranoside, and
amino acids were purchased from Sigma. All enzymes used for mole-
cular cloning were from Roche Molecular Biochemicals. The anti-goat
IgG antibody conjugated to horseradish peroxidase and nitrocellulose
membranes (0.45 μm; Hybond-C Extra) were from Amersham
Pharmacia Biotech. The enhanced chemiluminescence detection kit was
from Roche Molecular Biochemicals. All other chemicals used for
Sodium Dodecyl Sulfate (SDS)-polyacrylamide gel electrophoresis and
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Western blotting were purchased from Bio-Rad. A goat polyclonal an-
tibody (sc-54316) against the PKR2 amino-terminal region encom-
passing residues 1–18 was from Santa Cruz Biotechnology, anti-His
monoclonal antibodyhorseradish peroxidase conjugate was from Roche
Molecular Biochemicals. Mouse anti-STAT3 antibody and mouse anti-
pSTAT3 antibody were from Cell Signaling Technology and anti-beta-
actin antibody was from Abcam.
2.2. Animals and ethics statement
Experiments were carried out on male adult Sprague-Dawley rats
(Charles River, Como, Italy), weighting 280–320 g at the time of sur-
gery. Animals were two/cage housed, under conditions of optimum
light, temperature and humidity (12:12 h light/dark cycles, 22 ± 2 °C,
50–60% humidity) with food and water ad libitum.
All procedures involving animal care or treatments were approved
by the Animal Care and Use Committee of the Italian Ministry of Health
(authorization number: 79/2015-PR) and performed in compliance
with the IASP and European Community (E.C.L358/118/12/86)
guidelines. All efforts were made to minimize animal suffering and to
reduce the number of animals used.
2.3. Surgery and Aβ1–42 administration
Under ketamine-xylazine anaesthesia (60+10mg/kg in-
traperitoneally, i.p.), each rat was surgically implanted with a plastic
guide cannula (Linca, Tel-Aviv, Israel), stereotaxically inserted through
a skull hole drilled over the left lateral ventricle of the brain (1mm
caudal and 1.8mm lateral to the bregma). The cannula was screwed
into the skull hole and secured to the bone with dental cement. After
one week-recovery from surgery, Aβ1–42 (1 mg/ml; 5 μl injection vo-
lume) or its vehicle (PBS 5 μl injection volume) were i.c.v. injected, in a
constant volume of 5μl in awake rats, using a 10-μl Hamilton syringe
fitted with a 26-gauge needle that was inserted through the guide
cannula to a depth of 4.2mm below the external surface of the skull.
The needle was left in place for 10s after the end of the injection to
avoid reflux of the solute.
2.4. Yeast strains
The Saccharomyces cerevisiae strain used for PKR2 and TM 4–7 co-
expression was Cy12946 (MATa FUS1p-HIS3 GPA1Ga i2(5) can1
far1D1442 his3 leu2sst2D2 ste14::trp1::LYS2 ste3D1156 tbt1–1 trp1
ura3), a generous gift from Addison D. Ault (Princeton University,
USA). Specifically, Cy12946 expresses a chimeric Gα subunit (GPA1
Gαi2(5)) in which the carboxyl terminal five amino acids of the yeast Gα
subunit, GPA1, are replaced by the carboxyl-terminal five residues of
mammalian Gαi2. The use of GPA1 Gαi2(5) required deletion of SST2,
which down-regulates the pheromone response pathway by accel-
erating the GTPase activity of GPA1.
For ubiquitin split assay all yeast strains were generated from
NMY63.
To evaluate TM 4–7 activity after PROK2 binding we utilize yeast
strains MMY14, MMY23 and MMY28, generous gift of S. Dowell (Glaxo,
UK), isogenic except for the Gpa1 gene coding for the yeast G protein α
subunit Gpa1p. The three yeast strains harbor genomically integrated
mutant versions of Gpa1 coding for mutant Gpa1 proteins in which the
last five amino acids are replaced with the homologous mammalian
Gαq, Gαi1/2 and Gαs sequences, respectively. Normally, G protein-
mediated activation of the pheromone pathway leads to cell cycle ar-
rest; in these strains, instead, deletion of the Far1 gene allows yeast to
grow. The Sst2 gene was disrupted to prevent attenuation of G protein
signaling, mediated by the GTPase-activating protein Sst2p. The Ste2
gene coding for the yeast α-factor receptor was deleted to prevent
competition with heterologous expressed GPCRs for co-expressed G
proteins (Brown et al., 2011; Dowell and Brown, 2009).
DNA-mediated yeast transformation was carried out using a lithium
acetate method.
2.5. Yeast expression plasmids
The procedure to construct PKR2 pGAD has been previously de-
scribed (Marsango et al., 2011). cDNA of TM 4–7 splicing variant am-
plified by PCR, using as template PKR2-pGAD, with oligonucleotides
TM 4–7 BamHI up and PKR2 dw EcoRI was cloned in pYESC3 vector
(TM 4–7His). cDNA coding for TM 4–7 fused at C-terminal with His
TAG was obtained by digestion of TM 4–7His with BamHI and PmeI and
cloned in p426 vector digested with BamHI and SmaI (TM 4–7 p426).
The p426GPD vector contains the yeast GAPDH (glyceraldehyde-3-
phosphate dehydrogenase) promoter and the CYC1 terminator flanking
the multiple cloning sites (kind gift of Dr. S. Dowell). The full-length
PKR2 receptor and TM 4–7 splicing variant, were PCR-amplified and
cloned into the pGAD vector, where it was fused in frame to green
fluorescent protein (GFP) cDNA.
The PROK2 cDNAs, cloned downstream the α-factor signal se-
quence, contained in pPIC9K, were transferred by digestion with
BamHI-EcoRI in p413ADH under the control of the constitutive alcohol
dehydrogenase promoter (PROK2-p413). All oligonucleotides used for
plasmid constructions are listed in Table 1A.
2.6. Ubiquitin split assay: bait and prey constructs
The full-length PKR2 receptor and TM 4–7 splicing variant, were
PCR-amplified with oligonucleotides TM 4–7 NcoI/PKR2 NcoI and
PKR2 dw HindIII cloned into the pBT3 vector, where it was fused in
frame to the carboxyl terminal half of ubiquitin (Cub) and a tran-
scription factor (TF) consisting of Escherichia coli DNA-binding protein
LexA and the activation domain of VP16 from herpes simplex virus.
PKR2 cDNA were amplified with oligonucleotides PKR2 BamHI up and
PKR2 EcoRI dw and cloned into the pNubG-HA-X vector, pPR3.
2.7. Growth assay
Harvested cells were washed with distilled water and cell suspen-
sions were prepared to give an optical density (OD) at 600 nm of 10.
Seven microliters of serial dilutions of cell suspensions (1:10) were
spotted on Synthetic Defined (SD) Medium agar plates lacking leucine,
tryptophan, adenine and histidine. The plates were incubated at 30 °C.
2.8. Liquid β-galactosidase bioassays
Receptor activation was determined by measuring the induction of
β-galactosidase activity under the control of the FUS1 pheromone-in-
ducible promoter. Yeast cells were grown overnight to exponential
phase and diluted to give an OD at 600 nm of 0.2 by addition of sub-
strate/lysis solution (1mM fluorescein di-β-d-galactopyranoside, 0.1M
sodium phosphate, pH 7.3). Yeast cells were incubated for 22 h at 30 °C,
and the reactions were stopped by the addition of 20 μl of 1 mM sodium
carbonate. Fluorescence was read at an excitation wavelength of
475 nm and an emission wavelength of 520 nm at optimal gain (Dowell
and Brown, 2009). Duplicate samples were analyzed and the results
shown in the figures are representative of at least three independent
experiments.
2.9. Fluorescence imaging
Fluorescence images of cells expressing wild type and TM 4–7
tagged with GFP were captured by using a DAGE cooled CCD camera
mounted on an Olympus BH-2 microscope equipped with a
DPlanApo100UV 100× objective.
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2.10. Preparation of yeast membranes proteins
Yeast cells from a 1-liter overnight culture (1–2×107 cells/ml)
were collected by centrifugation, and membrane homogenates were
prepared using a glass bead method essentially as described previously
(Marsango et al., 2011). Membrane preparations (10 μg of protein/
sample) were mixed with an equal volume of 2-fold concentrated
Laemmli sample buffer (125mm Tris-HCl, pH 6.8, 20% glycerol, 4%
SDS, and 0.01% bromophenol blue) and incubated at 25 °C for 30min.
Proteins were separated on 10% SDS-polyacrylamide gels.
2.11. Western blot assay
After electrophoretic separation the proteins were transferred onto
nitrocellulose membrane and blocked in 1% non-fat Milk 1% BSA/Tris-
buffered saline with 0.10% Tween-20 (TBS-T pH 7.4) for 1 h at room
temperature. Then the membranes were incubated with the appropriate
primary antibody at a dilution of 1:1000 overnight at 4 °C in the
blocking solution. After extensive washing with TBS-T, the membranes
were incubated with anti-mouse IgG, HRP-linked secondary antibody
for 1 h at room temperature. Immunoreactive signals were visualized
with an enhanced chemiluminescence system.
2.12. RNA purification, reverse transcription and RT-PCR
Total RNA of rats, euthanized 1, 7, 14 and 35 days following Aβ1–42
(5 μg) i.c.v. injection, was extracted from brain hippocampus samples
using a TRIzol solution Invitrogen (Carlsbad, CA, USA) according to the
manufacturer's instructions. RNA yield and purity were determined by
spectrophotometry absorption at 260 and 280 nm and 1 μg of mRNA
was used to perform reverse transcription (Reverse Transcriptase,
Promega) to obtain cDNA that was used as template for RT-PCR and
real time-PCR using oligonucleotides showed in Table 1B.
Real time PCR (iCycler; Bio-Rad) was assessed using iQ SYBR Green
Supermix (Bio-line, London, U.K.). All the measures were performed in
triplicate. The reaction conditions were as follows: 95 °C for 10min
(Polymerase activation); followed by 35 cycles of 95 °C for 30s, an-
nealing step (Temp. depends on the Tm of primers) for 30s and elon-
gation at 72 °C for 30s. The reaction mixture without the cDNA was
used as control. The results were quantified using the comparative
threshold method. The Ct value of the specific gene of interest was
normalized to the Ct value of the endogenous control, glyceralde-hydes-
3-phosphate dehydrogenase (GAPDH), and the comparative Ct method
(2-ΔΔCt) was then applied using control healthy rats as the reference
samples.
For RT-PCR, cDNA was amplified using the Taq DNA Polymerase
with specific primers showed in Table 1B under the following condi-
tions: 95 °C for 5min; 40 cycles of 95 °C for 1min; annealing for 1min;
extension 72 °C for 1min; final extension 72 °C for 7min.
PCR products were separated by electrophoresis on 1.5% agarose
gel, visualized with ethidium bromide and analyzed using the Versa
Doc 3000 imaging system (Bio-Rad, Milan, Italy).
2.13. Analysis of STAT3 activation
Rat hippocampus was homogenized at 4 °C in 200 μl of Ripa buffer
containing protease inhibitors (1% v/v). Protein concentrations were
determined using the Bradford protein assay. Forty μg of proteins were
re-suspended in SDS-bromophenol blue loading buffer with 0.7 M 2-
mercaptoethanol. SDS-page gel was analyzed by western blotting assay
as described above. The quantification of the signal intensity of the
Western blot bands was performed with NIH ImageJ software. The
values are expressed as the mean ± SEM of 3 replications for each
antibody performed on 3 separate pools.
3. Results
3.1. Cloning of the Prokineticin receptor 2 variant, TM 4–7
In rat and mouse, Pkr2 genes are composed by three exons and two
introns. The first exon contains a 5′ untranslated sequence (UTR); the
second exon contains a part of the 5′ UTR sequence and a region en-
coding for the first three transmembrane domains TM1, TM2 and TM3;
the third exon encodes for the last transmembrane domains (TM4, TM5,
TM6 and TM7) and the 3′ UTR sequence (Fig. 1A). The second intron is
located at the TM3 border within the common DRY (Asp-Arg-Tyr) se-
quence. Intriguingly, the conservation of certain exon-intron bound-
aries and the relatively high sequence homology between rat and mouse
suggests that the Pkr2 genes are evolutionarily related. By computa-
tional process (Florea et al., 2005), alternatively spliced mRNA tran-
script in rat (accession number: EDL80264.1) and in mouse (accession
number: XM_011239558.2) for Pkr2 genes were predicted.
To evaluate the presence of PKR2 splicing variants in vivo, we de-
signed specific primers: a forward primer containing a sequence,
Table 1
Oligonucleotides used in this study.
A.
Oligonucleotide Sequence
TM4–7 BamHI up 5′- GAG GAT CCA TGG TGT CCA TTC TGG AGA AG-
3′
TM4–7 NcoI 5′-GAC CAT GGA TGG TGT CCA TTC TGG AGA AG-
3′
PKR2 NcoI 5′-GAC CAT GGA TGG CAG CCC AGA ATG G-3′
PKR2 dw EcorI 5′-TTG AAT TCC TTC AGC CTG ATA CAG TCC- 3′
PKR2dwHindIII 5′-GAA AGC TTC TTC AGC CTG ATA CAG TCC- 3′
B.
Gene Oligonucleotide Sequence Annealing temp (°C) PCR product (bp) Accession number
PKR2 5′UTRFw 5′-GGC GCC ACC GGC CAG GGA GTG CGT C-3 55 301 TM4–7 XM_006235059
Ex3Rev 5′-GCC TTG AAC CAG AGC TCT TGG GA G-3 873 PKR2 NM_138978
CH_473949
SOCS-3 Fw 5′-ACC AGC GCC ACT TCT TCA CA-3′ 55 450 NM_053565
Rev 5′-GTG GAG CAT CAT ACT GGT CC-3′
GAPDH Fw 5′-GCG AGA TCC CGC TAA CAT CAA ATG G-3′ 60 340 NM_017008
Rev 5′-GCC ATC CAC AGT CTT CTG AGT GGC-3′
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extreme conserved in exon 1, of mouse and rat Pkr2 gene (5′utrFw), and
a reverse primer based on a sequence of exon 3 (Ex3Rev). These primers
were used to amplify, by PCR assay, the cDNAs obtained by reverse
transcription of rat mRNAs hippocampus and cortex. Using rat hippo-
campus cDNA as template, we obtained two bands: one of about 350
and one of about 900 kb size (Fig.1B). Sequence analysis of fragments
indicates that one band encodes for the full-length of PKR2 and one is a
splicing variant of PKR2 generated by exon 2 skipping, denominated
TM 4–7. The TM 4–7 splicing variant containing only TM4, TM5, TM6
and TM7 is a receptor that lacks important sequences that may be
crucial for the recognition of ligand and for Gα coupling.
3.2. Physical association of TM 4–7 with PKR2
Mutant receptor was assessed for its ability to dimerize with PKR2
full-length. TM 4–7 terminal tagged His (TM 4–7His) was expressed
with untagged PKR2 full sequence (PKR2 pGAD) in yeast Cy12946. The
receptors were immunoprecipitated with the anti-His antibody, sub-
jected to SDS–page, and immuno-detected using a commercial poly-
clonal antibody raised against a peptide corresponding to the amino-
terminal 18-amino acids of PKR2, which does not recognize the TM 4–7
receptor. As seen in Fig. 2A, the anti-His immunoprecipitated detection
with the His antibody revealed the presence of the heterodimer TM
4–7/PKR2, with a molecular weight of 90 kDa, and of the dimer TM
4–7/TM 4–7 with a molecular weight of 45 kDa.
Detection of the anti-His immunoprecipitate with the PKR2 anti-
body (Fig. 2B), permitted to visualize only one band corresponding to
the heterodimer TM 4–7/PKR2.
The results were confirmed by in vivo experiments using split-
Ubiquitin Yeast Two hybrid system (Nakamura et al., 2013). Upon in
vivo protein-protein interaction, the reconstituted ubiquitin leads to
cleavage and release of LexA-VP16 by ubiquitin-specific proteases;
therefore, the protein interaction may be detected via the transcription
activation of the reporter genes (ADE, HIS3, and lacZ). To test the
viability of split-ubiquitin–based reporter gene assays for detecting
PKR2 dimers, we first analyzed the homodimerization of PKR2 receptor
in the NMY62 yeast strain. In NMY62 strain, were expressed two chi-
meric proteins: PKR2-NubG and PKR2-Cub-lexA.
PKR2-NubG was obtained fusing the N-terminal moiety of split-
ubiquitin, containing an I13G mutation (NubG), with PKR2 using the
original pPR3-C vector (prey). PKR2-Cub-lexA was obtained fusing the
C-terminal ubiquitin moiety, linked to an artificial transcription factor
(Cub-LexA-VP16) (Nakamura et al., 2013), to the C-termini of PKR2
receptors by using pBT3-C (bait) split-ubiquitin vector.
In particular, in yeasts coexpressing PKR2-NubG and/or PKR2-Cub-
lexA separately, we measured the β-galactosidase activities (Fig. 3A).
To validate this result, yeast strains were also grown on adenine/his-
tidine-deficient media (Fig. 3B). The results obtained indicate that the
split-ubiquitin-based approach could detect the homodimerization of
PKR2 receptors.
Then, we replaced a cDNA coding for full-length PKR2 with a cDNA
coding for the splicing variant TM 4–7 in pBT3-C (Fig. 3). These results
were coincident with immunoprecipitation experiments (Fig. 2)
showing TM 4–7 receptor ability to form heterodimers with full-length
PKR2.
Fig. 1. A. Scheme of alternative splicing of rat Pkr2 gene exons. Exon coding sequences are indicated as white bars and untranslated sequences are shown as gray
bars. B. Total RNA harvested from hippocampus (lane 1) and cortex (lane 2) was analyzed for PKR2 expression by RT-PCR. 10% of the PCR products were resolved on
1,5% agarose gel and stained with ethidium bromide. Positions of Standard markers are indicated on the left.
Fig. 2. Detection of TM 4–7 dimerization with PKR2 receptor in yeast strain by
immunoprecipitation. Membranes proteins from yeast immunoprecipitated
using Ni-NTA His bind resin were resolved by SDS-page. The immunoblots were
probed with anti-His (panel A) and anti-PKR2 (panel B) antibodies. Membranes
proteins from CyCp yeast strain expressing: Lane 1, TM 4–7 splicing variant;
Lane 2, CyCp; Lane 3, empty; Lane 4, PKR2 and TM 4–7 splicing variant.
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3.3. Yeast cell surface expression of TM 4–7 Prokineticin receptor variant
Because certain mutations in GPCR impair stability of receptors, it
was necessary to determine whether TM 4–7, being a receptor frag-
ment, trafficked normally to the plasma membrane. By fluorescence
microscopy we evidenced that GFP-tagged TM 4–7, like GFP-tagged
PKR2 wt receptor, localized on the plasma membrane (Fig. 4).
3.4. Functional expression of Prokineticin receptors and ligands in yeast
To investigate the activation mechanism of TM 4–7 splicing variant
by PROK2, we expressed TM 4–7, modified at the intracellular C-ter-
minus by incorporation of the His-tag, in three different yeast strains
carrying chimeras of 1–467 amino acid residues of yeast Gpa1 followed
by the last five amino acids of human Gαq (MMY14), Gαi (MMY23), and
Gαs (MMY28) (Fig. 5).
All yeast strains used in this study have been engineered so that
receptor signaling leads to activation of the yeast-mating pathway re-
sulting in the expression of a PFUS1-HIS3 and PFUS1-β-galactosidase
reporter gene (Dowell and Brown, 2009; Brown et al., 2011). This
system permits to evaluate the prokineticin receptors activation
(Lattanzi et al., 2018). Set of three yeast strains were obtained and
denominated MMY14 TM4–7, MMY28 TM 4–7, and MMY23 TM 4–7
respectively. Whole-cell extracts of yeast strains were analyzed by
Western blot using an antibody against His-Tag and we demonstrated
that the expression levels of TM 4–7 were comparable in different yeast
strains (Fig. 5A). Since it is difficult for large peptides to penetrate the
yeast cell wall, we decided to express PROK2 as an autocrine molecule.
We transformed each yeast strain with PROK2-p413 plasmid obtaining
a set of three yeast strains. Once assessed the expression level of TM
4–7, we performed a β-galactosidase assay using a fluorescein-con-
taining galactopyranoside analog that allowed the quantification of the
receptor activation by the measurement of the fluorescence signal at
530 nm.
The difference in β-galactosidase activity between cells expressing
or not PROK2, evidenced that TM 4–7 can be expressed in functionally
active and G protein-selective conformations to activate an endogenous
MAPK pathway in yeast cells (Fig. 5B). Data are presented as fold in-
duction with respect to control yeast expressing only ligand that ex-
hibited negligible FUS1-lacZ activation. Co-expression of TM 4–7 with
PROK2 clearly showed that the splicing variant coupled to Gαq, and Gαs
but not Gαi (Fig. 5C). Relative maximal FUS1-lacZ was calculated re-
spect to values obtained with PKR2 (Lattanzi et al., 2018).
We analyzed if co-expression of TM 4–7 with PKR2 wt could mod-
ulate activity of full length receptor evaluating β-galactosidase activity
of yeast strain Cy12946 transformed with TM 4–7His, PKR2 pGAD and
Fig. 3. Detection of TM 4–7 dimerization with PKR2 by ubiquitin split assay. Yeast Cells expressing different combinations of Cub and NubG fusion proteins were
analyzed by: A. Quantitative β-galactosidase assay. B. Growth assay: each cells colture was spotted in serial 10-fold dilutions on SD-Leu, Trp, Ade and His dropout
plate. The control prey plasmid was pBT3c vector. Data are expressed as mean of five independent experiments ± SEM. Data were determined as significantly
different from response induced in yeast transfected with only one vector. Student's t-test was used for statistical evaluation: ***p < 0.001 PKR2/TM 4–7 vs TM 4–7;
°°°p < 0.001 PKR2/PKR2 vs PKR2.
Fig. 4. Fluorescence confocal microscopy analysis showing plasma membrane localization of TM 4–7 and PKR2. Scale bar 10 μm.
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PROK2-p413. The results obtained demonstrated a drastic reduction of
Gαi activation (about 45%).
3.5. Up-regulation of TM 4–7 following Aβ insult
In hippocampus from adult rats we evaluated, by RT-PCR analysis,
TM 4–7 and PKR2 mRNA levels 7, 14 and 35 days after Aβ1–42 i.c.v.
injection.
Time-course analysis (7, 14, 35days) indicated that TM 4–7 mRNA
was progressively increased 7, 14 and 35days after Aβ1–42 injection,
whereas PKR2 mRNA showed a biphasic pattern of expression, with an
increase at 7 and 14 days followed by a decrease at 35 days when its
levels appeared overlapped to that of controls (Fig. 6).
3.6. STAT3 activation and Socs-3 gene expression in rat hippocampus after
Aβ treatment
We evaluated, by western blotting experiments, the STAT3
phosphorylation in rat brain hippocampus 14 and 35 days after Aβ1–42
i.c.v. injection. Rat hippocampal tissues were homogenized, and the
lysates were gel transferred on nitrocellulose membrane and incubated
with STAT3 and p-STAT3 antibodies.
In rat hippocampus, there was a STAT3 phosphorylation sig-
nificantly higher respect to control animals only 14 days after Aβ1–42
treatment; this activation was not abolished by pretreatment with the
PKRs antagonist PC1 (Fig. 7A). Conversely, 35 days after Aβ1–42 injec-
tion the p-STAT3 levels were lower than that observed in control ani-
mals (Fig. 7A).
STAT3 regulates transcription of Socs-3 gene (Kershaw et al., 2013).
An increase in SOCS-3 mRNA levels was observed in hippocampus of
rats scarified 14 days after Aβ1–42 administration, respect to control
animals (Fig. 7B, C). 35 days after Aβ1–42 injection the SOCS-3 mRNA
levels were lower than that observed in controls (Fig. 7B, C).
Fig. 5. TM 4–7 induces preferentially Gαq, Gαs, but
not Gαi, coupling. (A) Expression of Prokineticin
receptors. Cells extract expressing PKR2-HIS and TM
4–7HIS were resolved by SDS-page. Western blots
were probed with an anti-his-antibody, stripped and
reprobed with an anti-beta actin antibody as a
loading contr. (B) Yeast strains MMY14, MMY28,
and MMY23 expressing the receptor PKR2 (dark gray
bar) or the receptor TM 4–7 and the ligand PK2 (light
gray bar). The resulting fluorescence activity was
measured at 485 nm excitation, 530 nm emission.
Data from each experiment are presented as a re-
lative β-galactosidase activity (fold induction rather
than absolute values). Data are presented as fold
induction with respect to control yeast expressing
only ligand that exhibited negligible FUS1-lacZ acti-
vation. Data are mean five independent
experiments± SEM. Data were determined as sig-
nificantly different from the non peptide response
using Student's t-test where ***p < 0.001. (C) β-
galactosidase activity in yeast strains MMY14,
MMY28 and MMY23 expressing Gαq, Gαs and Gαi
proteins respectively, and the receptor TM 4–7.
Relative maximal FUS1-lacZ induction was calcu-
lated with respect to wild type PKR2 receptors when
induced with the highest concentration of ligands.
Data are mean five independent experiments± SEM.
Fig. 6. Expression of TM 4–7 and PKR2 following Aβ insult. A. Analysis of PCR amplicons by gel electrophoresis. The left lane indicates the molecular marker. B.
Ratio between TM 4–7 and PKR2 mRNA was analyzed by NIH ImageJ software. The mRNA expression levels were expressed in relation to GAPDH. Data represent
means (± SEM) from at least 4 independent experiments and the statistically significant differences were calculated by Student's t-test **p < 0.01, ***p < 0.001 vs
CTR (PKR2); °p < 0.05, °°p < 0.01 vs CTR (TM 4–7); §§p < 0.01 TM 4–7 35d vs PKR2 35d.
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4. Discussion
Alternative splicing is a ubiquitous regulatory mechanism of gene
expression that allows generation of more than one unique mRNA
species from a single gene through mechanisms that include the re-
moval of specific exons, exon skipping, a choice between mutually
exclusive exons and the use of alternative splice sites. Strong splice sites
with consensus sequences are always recognized by the spliceosome
machinery and determine a constitutive splicing. Weak splice sites
differ from consensus sequences, and their recognition by the spliceo-
some is highly dependent by the presence of cis-acting sequences and
the cellular context, such as splicing-factor expression levels (Chen and
Manley, 2009). Alternative splicing of GPCR increases receptor iso-
forms and signal options in health and disease (Markovic and Challiss,
2009; Wise, 2012). Sequence analysis of the mouse and rat genome
indicates that Pkr2 gene consists of three exons and two introns. Also
mouse Pkr1 gene is composed by three exons although in the past was
suggested to consist only of two exons (Parker et al., 2000). The posi-
tions and sequences of the splice donor and acceptor sites and the
length of exons are exactly the same for mouse and rat Pkr2 genes. In
contrast, the length of the introns considerably varies as well as their
sequences.
By informatic study (Florea et al., 2005) it was possible to predict
the splicing variant of murine and rat Pkr2 gene. Given the differences
in the genomic intron sequences, it is not obvious that all the splice
variants present in one species also occur in other species. The creation
of PKR2 knock out mice, by transposon insertion inside the intron 2,
allowed the authors to found two transcripts: one, containing exon 1
and exon 2, due to the block of transcription for the presence of the
transposon, and one containing exon 1 and 3, due to excision of exon 2
and transposon (Prosser et al., 2007).
This result can be explained, in the light of our data, as the first
evidence of the presence of alternative PKR2 splicing transcripts in
vivo.
We identified the PKR2 splicing variant, TM 4–7, in rat hippo-
campus whereas it was undetectable in rat cortex. Moreover, in this
study we characterized the truncated PKR2 receptor by expression in
yeast heterologous system. We have previously shown that PKR2 forms
active dimers in physiologically relevant cell types and in heterologous
expression system (Marsango et al., 2011; Sposini et al., 2015). We
evidenced the capacity of TM 4–7 receptor to form heterodimers with
PKR2 receptor by immunoprecipitation assay. To confirm in vivo im-
munoprecipitation data we used the split-ubiquitin membrane yeast
two hybrid technology. Unlike the Yeast Two Hybrid (YTH), the split-
ubiquitin membrane YTH is not limited to the analysis of soluble pro-
teins thus offers the opportunity to identify membrane protein inter-
actions as they take place in their natural setting (Nakamura et al.,
2013). TM 4–7 is still able to interact with PKR2 according to our
previous data showing that PKR2 protomers involve TM4 and TM5
(Sposini et al., 2015). To investigate if TM 4–7 is activated by PROK2,
we expressed the mutant receptor in yeast strains (Dowell and Brown,
2009; Brown et al., 2011) that only differ in the nature of the Gα
protein subunit present. The splicing variant partially retained signal
transduction activity by Gαs and Gαq coupling but it completely lost
activity in the presence of Gαi. Co-transfection of TM 4–7 in cells ex-
pressing PKR2 negatively modulates Gαi.-induced signal responses.
In the past (Sposini et al., 2015), we have created a PKR2 variant,
TM 1–5, obtained deleting the last two transmembrane domains and the
carboxyl-terminal tail, that is still able to form dimers with PKR2. TM
1–5 alone does not exert in vitro signal transduction activity, however,
when it is co-expressed with the PKR2, it markedly exhibits ligand-in-
duced calcium responses. These our data are confirmed in a study
conducted in patients with precocious puberty which overexpress the
TM 1–5 PKR2 variant (Fukami et al., 2017). Truncated receptors, TM
1–5 and TM 4–7, which share only the region spanning TM4 and TM5
crucial for the dimer formation, are both able to interact with PKR2 but
they modulate the PKR2 receptor activity in a different fashion.
Data from our laboratory, showed that, in the animal model of AD
induced by Aβ1–42 i.c.v. injection in rat (Selkoe, 2001; Rubio-Perez and
Morillas-Ruiz, 2012) there was a significant increase in PKR2 mRNA
levels not corresponding to PKR2 protein levels increase, detected by an
antibody against the PKR2 N-terminal region (data in publication). It
has been demonstrated that, in AD, there is a modulation of alternative
splicing of genes, notoriously involved in this pathology, like the β-
amyloid precursor protein, TAU, and apolipoprotein E (Love et al.,
2015). For this reason we decided to investigate if TM 4–7 receptor
isoform could be regulated in the animal model of AD, induced by
Aβ1–42 i.c.v. injection in rat and we found that TM 4–7 receptor isoform
is strongly up- regulated and the expression ratio between the PKR2
splicing variant and the PKR2 long form significantly and progressive
increased 14 and 35 days after Aβ insult in rat hippocampus.
So, we evaluated if TM 4–7 increased levels could induce an al-
teration in Gαi-mediated response after PROK2 binding. As reported in
literature, PROK2 is able to induce STAT3 phosphorylation (Qu et al.,
2012; Xin et al., 2013) and we demonstrated that, in rat dorsal root
ganglia explants, PROK2 is able to induce STAT3 activation through
Gαi because it is abolished by pertussis toxin pretreatment (Lattanzi
et al., 2018).
Fig. 7. STAT3 activation and SOCS-3 expression 14 and 35 days after Aβ treatment. A. Representative Western blot analysis showing phospho-STAT3 (p-STAT3) and
STAT3 protein amounts 14 and 35 days after Aβ insult. Data are express as mean ± SEM. Statistical analyses were performed using Student's t-test where *p < 0.05
vs Veh i.c.v./Veh s.c. B, C. RT-PCR and Real Time RT-PCR analysis showing SOCS-3 mRNA levels in hippocampus of rat 14 and 35 days after Aβ1–42 injection. The
mRNA expression levels were expressed in relation to GAPDH. Data are express as mean ± SEM. Statistical analyses were performed using Student's t-test where
#p < 0.05, ##p < 0.01 vs Veh i.c.v./Veh s.c.; °°p < 0.01, °°°p < 0.001 vs Aβ i.c.v./Veh s.c. 14d.
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In rat hippocampus, 14 days after Aβ administration there was a
significant p-STAT3 increase respect to hippocampus from control an-
imals. Despite the presence of high levels of PROK2 (data in publica-
tion), STAT3 phosphorilation did not involve PKR2 activation because
it was not abolished by PC1 (the PKR antagonist) pretreatment (Balboni
et al., 2008; Lattanzi et al., 2014). This suggested us that the presence of
high levels of TM 4–7 prevented PROK2-induced STAT3 phosphorila-
tion. Conversely, 35 days after Aβ treatment was not possible to de-
termine STAT3 activation, according to data showing that Aβ chronic
stimulation there are very low p-STAT3 levels in hippocampal neurons
(Chiba et al., 2009). These data were confirmed by suppressor of cy-
tokine signaling (SOCS-3) expression analysis. SOCS proteins are the
key anti-inflammatory regulators of JAK–STAT pathways and their
expression is up-regulated after STAT activation (Kershaw et al., 2013).
Notably, high levels of SOCS3 are correlated with Aβ deposition
(Cianciulli et al., 2017). Our data indicate that SOCS3 levels are ele-
vated 14 days after Aβ1–42 injection but not 35 days after Aβ insult
correlating with STAT3 activation.
TM 4–7 could generate functionally active receptors by hetero-
dimerization with PKR2, like other truncated splice variants of GPCR
(Markovik and Challiss, 2009; Wise, 2012; Xu et al., 2013), or could
form active homodimers as described for chemokine receptors (Ling
et al., 1999).
TM 4–7, both as heterodimer and homodimer, shows different
functional characteristics respect to PKR2 dimers. The different TM 4–7
receptor distribution, in physiological and in pathologic conditions,
suggests a versatile way of regulation of brain functions which adds
another layer of complexity onto the Prokineticin system.
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